semaglutide breakouts A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists Granuloma annulare after starting semaglutide

doi: 10.1111/j.1460-9568.2004.03485.x

K., Kohli, S., Mustian, K

[DOI] [PubMed] [Google Scholar] 71.Tominaga M, Song GB, Ikemoto F, Yamamoto K

Wegovy is FDA-approved for two indications : Weight loss in people with obesity and overweight Cardiovascular risk reduction in people with heart disease and obesity or overweight To get Wegovy for weight loss , you must fall into one of the following categories : Adults with a body mass index (BMI) of 30 or above (defined as obesity) Adults with a BMI of 27 or higher (defined as overweight) and a weight-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea Children ages 12 and up with obesity, defined in children as having a BMI in the 95th percentile (or higher) for their age and sex To take Wegovy to reduce your cardiovascular risk, you must have heart disease and either obesity or overweight (using the BMI definitions above)

Diarrhea is a result of intestinal inflammation